IL267331B2 - Process For The Preparation Of A Mono-Phosphate Salt Crystal Of (6aR,9aS)-5,6a,7,8,9,9a-Hexahydro-5-Methyl-3-(Phenylamino) -2-((4-(6-Fluoropyridin-2-yl)Phenyl)Methyl)-Cyclopent[4,5]Imidazo[1,2-A] -Pyrazolo[4,3-E]Pyrimidin-4(2H)-One - Google Patents
Process For The Preparation Of A Mono-Phosphate Salt Crystal Of (6aR,9aS)-5,6a,7,8,9,9a-Hexahydro-5-Methyl-3-(Phenylamino) -2-((4-(6-Fluoropyridin-2-yl)Phenyl)Methyl)-Cyclopent[4,5]Imidazo[1,2-A] -Pyrazolo[4,3-E]Pyrimidin-4(2H)-OneInfo
- Publication number
- IL267331B2 IL267331B2 IL267331A IL26733119A IL267331B2 IL 267331 B2 IL267331 B2 IL 267331B2 IL 267331 A IL267331 A IL 267331A IL 26733119 A IL26733119 A IL 26733119A IL 267331 B2 IL267331 B2 IL 267331B2
- Authority
- IL
- Israel
- Prior art keywords
- methyl
- free base
- crystal
- pyrazolo
- pyrimidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361838105P | 2013-06-21 | 2013-06-21 | |
| US201361919424P | 2013-12-20 | 2013-12-20 | |
| PCT/US2014/043422 WO2014205354A2 (en) | 2013-06-21 | 2014-06-20 | Free base crystals |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL267331A IL267331A (en) | 2019-08-29 |
| IL267331B1 IL267331B1 (en) | 2024-08-01 |
| IL267331B2 true IL267331B2 (en) | 2024-12-01 |
Family
ID=52105535
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL267331A IL267331B2 (en) | 2013-06-21 | 2014-06-20 | Process For The Preparation Of A Mono-Phosphate Salt Crystal Of (6aR,9aS)-5,6a,7,8,9,9a-Hexahydro-5-Methyl-3-(Phenylamino) -2-((4-(6-Fluoropyridin-2-yl)Phenyl)Methyl)-Cyclopent[4,5]Imidazo[1,2-A] -Pyrazolo[4,3-E]Pyrimidin-4(2H)-One |
| IL243269A IL243269B (en) | 2013-06-21 | 2015-12-21 | Crystals of (sa9,ra6)-a9,9,8,7,a6,5-hexahydro-5-methyl-3-(phenylamino)-2- ((4-(6-fluoropyridin-2-yl)phenyl)methyl ) cyclopent[5,4]imidazo[a-2,1]pyrazolo[e-3,4]pyrimidine-4(h2)-one, their salts and a process for preparing the salts. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL243269A IL243269B (en) | 2013-06-21 | 2015-12-21 | Crystals of (sa9,ra6)-a9,9,8,7,a6,5-hexahydro-5-methyl-3-(phenylamino)-2- ((4-(6-fluoropyridin-2-yl)phenyl)methyl ) cyclopent[5,4]imidazo[a-2,1]pyrazolo[e-3,4]pyrimidine-4(h2)-one, their salts and a process for preparing the salts. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9630971B2 (enExample) |
| EP (2) | EP3010509B1 (enExample) |
| JP (2) | JP6865036B2 (enExample) |
| KR (2) | KR20160040522A (enExample) |
| CN (3) | CN112851683A (enExample) |
| AU (1) | AU2014284224B2 (enExample) |
| BR (1) | BR112015032132B1 (enExample) |
| CA (1) | CA2916393C (enExample) |
| ES (1) | ES2894770T3 (enExample) |
| IL (2) | IL267331B2 (enExample) |
| MX (2) | MX2015017972A (enExample) |
| RU (1) | RU2675851C2 (enExample) |
| WO (1) | WO2014205354A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10561656B2 (en) | 2011-06-10 | 2020-02-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| AR091507A1 (es) | 2012-06-21 | 2015-02-11 | Intra Cellular Therapies Inc | SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA |
| EP3010509B1 (en) | 2013-06-21 | 2021-07-28 | Intra-Cellular Therapies, Inc. | Free base crystals |
| EP4413980A3 (en) | 2019-09-03 | 2024-10-30 | Intra-Cellular Therapies, Inc. | Novel compounds |
| US12435093B2 (en) | 2020-05-06 | 2025-10-07 | Intra-Cellular Therapies, Inc. | Free base crystals |
| JP2023535224A (ja) * | 2020-07-26 | 2023-08-16 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
| EP4395767A4 (en) * | 2021-09-03 | 2025-07-23 | Intra Cellular Therapies Inc | CO-CRYSTALS |
| US20250144029A1 (en) * | 2022-01-27 | 2025-05-08 | Intra-Cellular Therapies, Inc. | Novel compositions |
| WO2023233410A1 (en) * | 2022-06-02 | 2023-12-07 | Biosight Ltd. | Crystalline form of aspacytarabine intermediate |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9412571D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| US5471001A (en) * | 1994-12-15 | 1995-11-28 | E. I. Du Pont De Nemours And Company | Crystallization of adipic acid |
| GB9624615D0 (en) | 1996-11-26 | 1997-01-15 | Zeneca Ltd | Chrystallisation process |
| TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| WO2003066590A1 (en) | 2002-02-08 | 2003-08-14 | Ono Pharmaceutical Co., Ltd. | Piperidine derivative compounds and drugs containing the compounds as the active ingredient |
| EP1613747A1 (en) * | 2003-03-31 | 2006-01-11 | Pfizer Products Inc. | Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof |
| AU2004268024B2 (en) | 2003-09-02 | 2007-07-12 | Merck Sharp & Dohme Llc | Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
| DK1794126T3 (da) * | 2004-09-27 | 2013-06-24 | Acadia Pharm Inc | Krystallinsk form af N-(-4-fluorbenzyl)-N-(1-methylpiperidn-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamid-hemitartrat |
| CN101248050B (zh) | 2005-06-06 | 2013-07-17 | 武田药品工业株式会社 | 有机化合物 |
| WO2008063505A1 (en) | 2006-11-13 | 2008-05-29 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9006258B2 (en) | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
| WO2009075784A1 (en) | 2007-12-06 | 2009-06-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US20120070443A1 (en) | 2008-12-02 | 2012-03-22 | University Of Utah Research Foundation | Pde1 as a target therapeutic in heart disease |
| EP2367429B1 (en) | 2008-12-06 | 2017-06-07 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP2358204B1 (en) | 2008-12-06 | 2015-08-05 | Intra-Cellular Therapies, Inc. | 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors. |
| CN102232077A (zh) | 2008-12-06 | 2011-11-02 | 细胞内治疗公司 | 有机化合物 |
| EP2400970A4 (en) | 2009-02-25 | 2012-07-18 | Intra Cellular Therapies Inc | PDE-1-HEMMER FOR EYE DRESSING |
| US9468637B2 (en) * | 2009-05-13 | 2016-10-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP2013507360A (ja) | 2009-10-08 | 2013-03-04 | イントラ−セルラー・セラピーズ・インコーポレイテッド | ホスホジエステラーゼ１−標的トレーサーおよび方法 |
| JP5911854B2 (ja) | 2010-05-31 | 2016-04-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| US10561656B2 (en) | 2011-06-10 | 2020-02-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| AR091507A1 (es) * | 2012-06-21 | 2015-02-11 | Intra Cellular Therapies Inc | SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA |
| EP3010509B1 (en) | 2013-06-21 | 2021-07-28 | Intra-Cellular Therapies, Inc. | Free base crystals |
-
2014
- 2014-06-20 EP EP14812994.3A patent/EP3010509B1/en active Active
- 2014-06-20 BR BR112015032132-1A patent/BR112015032132B1/pt active IP Right Grant
- 2014-06-20 AU AU2014284224A patent/AU2014284224B2/en active Active
- 2014-06-20 ES ES14812994T patent/ES2894770T3/es active Active
- 2014-06-20 CA CA2916393A patent/CA2916393C/en active Active
- 2014-06-20 US US14/900,589 patent/US9630971B2/en active Active
- 2014-06-20 CN CN202110144523.3A patent/CN112851683A/zh active Pending
- 2014-06-20 CN CN201480046150.4A patent/CN105658222A/zh active Pending
- 2014-06-20 EP EP20165092.6A patent/EP3702358A1/en active Pending
- 2014-06-20 RU RU2016101630A patent/RU2675851C2/ru active
- 2014-06-20 JP JP2016521847A patent/JP6865036B2/ja active Active
- 2014-06-20 KR KR1020167001273A patent/KR20160040522A/ko not_active Ceased
- 2014-06-20 IL IL267331A patent/IL267331B2/en unknown
- 2014-06-20 KR KR1020217030964A patent/KR102430126B1/ko active Active
- 2014-06-20 CN CN201910526464.9A patent/CN110498800A/zh active Pending
- 2014-06-20 MX MX2015017972A patent/MX2015017972A/es active IP Right Grant
- 2014-06-20 WO PCT/US2014/043422 patent/WO2014205354A2/en not_active Ceased
-
2015
- 2015-12-21 IL IL243269A patent/IL243269B/en active IP Right Grant
- 2015-12-21 MX MX2020001628A patent/MX2020001628A/es unknown
-
2019
- 2019-06-04 JP JP2019104412A patent/JP2019189618A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267331B2 (en) | Process For The Preparation Of A Mono-Phosphate Salt Crystal Of (6aR,9aS)-5,6a,7,8,9,9a-Hexahydro-5-Methyl-3-(Phenylamino) -2-((4-(6-Fluoropyridin-2-yl)Phenyl)Methyl)-Cyclopent[4,5]Imidazo[1,2-A] -Pyrazolo[4,3-E]Pyrimidin-4(2H)-One | |
| US9469647B2 (en) | Salt crystals | |
| CN108699063A (zh) | 一种芦可替尼的合成工艺 | |
| CN107155326A (zh) | (2s,3s)‑7‑氟‑2‑(4‑氟苯基)‑3‑(1‑甲基‑1h‑1,2,4‑三唑‑5‑基)‑4‑氧代‑1,2,3,4‑四氢喹啉‑5‑羧酸甲酯的共形成体盐及其制备方法 | |
| US12435093B2 (en) | Free base crystals | |
| HK40036801A (en) | Process for preparing salts of a known pde1 inhibitor | |
| HK1223848B (en) | Free base crystals | |
| HK40090878A (zh) | 用於制备1-甲基-6-[6-r2-5-甲基-8-(甲基氨基)-4-[(3as，6as)-5-甲基-2，3，3a，4，6，6a-六氢吡咯并[2，3-c]吡咯-1-基]-9h-吡啶并[2，3-b]吲哚-3-基]-4-氧代-1，8-萘啶-3-甲酸盐酸盐的方法 | |
| IL303354A (en) | Process for the preparation 4-(3,5-difluorophenyl)-n-[3-(6-methylpyrimidin-4-yl)-3- azabicyclo[3.2.1]octan-8-yl]-6,7-dihydro-5h-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine | |
| WO2022076703A1 (en) | Processes for preparing a pan-jak inhibitor and related intermediate compounds | |
| HK1247191A1 (en) | Salt crystals | |
| HK1210017B (en) | Salt crystals of a pde1 inhibitor | |
| PL223869B1 (pl) | Sposób otrzymywania wardenafilu i jego soli |